David A. Siegel Prothena Corp Public LTD CO Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q3 2024

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$24.75 - $40.66 $3.43 Million - $5.63 Million	-138,500 Reduced 94.35%	8,300 $205,000
Q4 2023 Feb 14, 2024	SELL	$32.31 - $52.32 $1.84 Million - $2.98 Million	-57,000 Reduced 27.97%	146,800 $5.33 Million
Q3 2023 Nov 14, 2023	SELL	$47.3 - $70.6 $2.96 Million - $4.41 Million	-62,500 Reduced 23.47%	203,800 $9.83 Million
Q2 2023 Aug 14, 2023	SELL	$48.26 - $78.59 $5.55 Million - $9.04 Million	-115,000 Reduced 30.16%	266,300 $18.2 Million
Q1 2023 May 15, 2023	BUY	$46.97 - $58.27 $2.55 Million - $3.16 Million	54,300 Added 16.61%	381,300 $18.5 Million
Q4 2022 Feb 14, 2023	SELL	$52.05 - $65.0 $416,400 - $520,000	-8,000 Reduced 2.39%	327,000 $19.7 Million
Q3 2022 Nov 14, 2022	SELL	$25.16 - $60.63 $2.84 Million - $6.83 Million	-112,700 Reduced 25.17%	335,000 $20.3 Million
Q3 2022 Nov 14, 2022	SELL	$25.16 - $60.63 $2.84 Million - $6.83 Million	-112,700 Reduced 25.17%	335,000 $20.3 Million
Q2 2022 Aug 15, 2022	BUY	$22.73 - $39.98 $715,995 - $1.26 Million	31,500 Added 7.57%	447,700 $12.2 Million
Q1 2022 May 16, 2022	BUY	$30.27 - $49.22 $236,106 - $383,916	7,800 Added 1.91%	416,200 $15.2 Million
Q4 2021 Feb 14, 2022	SELL	$42.11 - $73.26 $2.75 Million - $4.78 Million	-65,300 Reduced 13.79%	408,400 $20.2 Million
Q3 2021 Nov 15, 2021	BUY	$48.2 - $78.89 $2.48 Million - $4.05 Million	51,400 Added 12.17%	473,700 $33.7 Million
Q2 2021 Aug 16, 2021	BUY	$21.63 - $57.65 $1.63 Million - $4.35 Million	75,500 Added 21.77%	422,300 $21.7 Million
Q1 2021 May 17, 2021	BUY	$11.0 - $28.24 $1.88 Million - $4.82 Million	170,600 Added 96.82%	346,800 $8.71 Million
Q4 2020 Feb 16, 2021	SELL	$10.12 - $13.94 $358,248 - $493,476	-35,400 Reduced 16.73%	176,200 $2.12 Million
Q3 2020 Nov 16, 2020	SELL	$9.93 - $13.47 $31,776 - $43,104	-3,200 Reduced 1.49%	211,600 $2.11 Million
Q2 2020 Aug 14, 2020	BUY	$9.56 - $12.51 $104,204 - $136,359	10,900 Added 5.35%	214,800 $2.25 Million
Q1 2020 May 15, 2020	BUY	$7.54 - $15.77 $21,112 - $44,156	2,800 Added 1.39%	203,900 $2.18 Million
Q4 2019 Feb 14, 2020	SELL	$7.48 - $17.01 $146,608 - $333,396	-19,600 Reduced 8.88%	201,100 $3.18 Million
Q3 2019 Nov 14, 2019	SELL	$6.89 - $10.45 $377,572 - $572,660	-54,800 Reduced 19.89%	220,700 $1.73 Million
Q2 2019 Aug 14, 2019	SELL	$8.85 - $12.49 $38,940 - $54,956	-4,400 Reduced 1.57%	275,500 $2.91 Million
Q1 2019 May 15, 2019	BUY	$10.32 - $14.49 $1.47 Million - $2.06 Million	142,200 Added 103.27%	279,900 $3.4 Million
Q4 2018 Feb 14, 2019	BUY	$8.73 - $13.74 $660,861 - $1.04 Million	75,700 Added 122.1%	137,700 $1.42 Million
Q3 2018 Nov 14, 2018	BUY	$12.7 - $15.79 $617,220 - $767,394	48,600 Added 362.69%	62,000 $811,000
Q2 2018 Aug 14, 2018	BUY	$10.99 - $44.21 $147,266 - $592,414	13,400 New	13,400 $195,000

Others Institutions Holding PRTA

# of Institutions

184

Shares Held

42.7M

Call Options Held

162K

Put Options Held

102K

Eco R1 Capital, LLC San Francisco, CA

11.6M
Shares

$176 Million
8.41% of portfolio
Wellington Management Group LLP Boston, MA

4.18M
Shares

$63.6 Million
0.01% of portfolio
Black Rock Inc. New York, NY

3.86M
Shares

$58.7 Million
0.0% of portfolio
Price T Rowe Associates Inc Baltimore, MD

3.82M
Shares

$58.2 Million
0.01% of portfolio
Palo Alto Investors LP Palo Alto, CA

1.74M
Shares

$26.5 Million
4.0% of portfolio

View Full List

About PROTHENA CORP PUBLIC LTD CO

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $714M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

More about PRTA

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account